GNTA today
$0.98+$0.17 (+20.62%)close Nov 3, 2026Trend
DailyUptrend (starting)
4 hourStrong Bullish
1 hourStrong Bullish
15 minLeaning Bearish
5 minStrong Bullish
Daily trend turns down below $0.55
Key levels
Resistance$1.20
Resistance$1.06
Support$0.95
Support$0.85
Latest news & SEC filings
LegalGenenta Science Gets Nasdaq Minimum Bid Price Deficiency Notice
All GNTA news →About Genenta Science
Genenta Science is a clinical-stage biotechnology company developing ex-vivo gene therapies for solid tumors. Its lead candidate, Temferon, modifies a patient's own hematopoietic stem cells to deliver interferon-alpha to the tumor microenvironment, and is being studied in glioblastoma. The company also announced plans to expand into acquiring businesses in defense, aerospace, and national security sectors. It is based in Milan, Italy, and its shares trade on Nasdaq.
Based on the company's 20-F filed Apr 1, 2026.
Nasdaq · Healthcare
Genenta Science S.p.A. (GNTA)
What Is the Price Target for GNTA?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is GNTA a Buy or Sell Right Now?
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for GNTA.
Start Free Trial →Is GNTA Overvalued or Undervalued?
Valuation Verdict
N/A
Methods Used
N/A
Fair Value
$N/A
0
Moat Score
NONE
2/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with GNTA?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →GNTA Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
29.74%
FCF Growth YoY
-14.9%
Revenue Trend
UNKNOWN
Dark Pool Trades for GNTA
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for GNTA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 24:43:33 | $1.08 | 1,106 | $$1K | SELL |
| 24:35:06 | $1.19 | 1,455 | $$2K | BUY |
| 24:35:03 | $1.19 | 2,700 | $$3K | BUY |
| 24:35:02 | $1.19 | 2,700 | $$3K | BUY |
| 24:35:01 | $1.19 | 2,700 | $$3K | BUY |
5 dark pool trades shown · $$13K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Genenta Science S.p.A. (GNTA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →GNTA — frequently asked questions
What is GNTA stock price today?
Genenta Science S.p.A. (GNTA) is at $0.98, up 20.62% (+$0.17) at the Nov 3, 2026 close.
Why is GNTA stock moving today?
Latest GNTA news — Oct 22, 2026: Genenta Science Gets Nasdaq Minimum Bid Price Deficiency Notice
Did GNTA beat earnings?
GNTA last reported on Mar 31, 2026: EPS -$0.36 vs -$0.36 expected — in line.
Does GNTA pay a dividend?
GNTA does not currently pay a dividend.
What are GNTA support and resistance levels?
Support: $0.95, $0.85, $0.70. Resistance: $1.06, $1.20, $1.30.
What are insiders doing with GNTA?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on GNTA?
Oct 22, 2026: Genenta Science Gets Nasdaq Minimum Bid Price Deficiency Notice